Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure

• Үндсэн зохиолчид: Claudia Augusta Di Trani (Зохиогч), Assunta Cirella (Зохиогч), Leire Arrizabalaga (Зохиогч), Maite Alvarez (Зохиогч), Ángela Bella (Зохиогч), Myriam Fernandez-Sendin (Зохиогч), Joan Salvador Russo-Cabrera (Зохиогч), Celia Gomar (Зохиогч), Nuria Ardaiz (Зохиогч), Alvaro Teijeira (Зохиогч), Elixabet Bolaños (Зохиогч), José González-Gomariz (Зохиогч), Itziar Otano (Зохиогч), Fernando Aranda (Зохиогч), Belén Palencia (Зохиогч), Aina Segués (Зохиогч), Shuyu Huang (Зохиогч), Sander M.J. van Duijnhoven (Зохиогч), Andrea van Elsas (Зохиогч), Ignacio Melero (Зохиогч), Pedro Berraondo (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Elsevier, 2023-09-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

IL-12 is a potent cytokine for cancer immunotherapy. However, its systemic delivery as a recombinant protein has shown unacceptable toxicity in the clinic. Currently, the intratumoral injection of IL-12-encoding mRNA or DNA to avoid such side effects is being evaluated in clinical trials. In this st...